Cargando…
Development and Performance Verification of the PBPK Model for Antazoline and Its Metabolite and Its Utilization for Pharmacological Hypotheses Formulating
Antazoline is an antihistaminic drug that is effective in the termination of paroxysmal atrial fibrillation. Despite its long presence in the market, antazoline’s ADME parameters and pharmacokinetic effects in humans are poorly characterized. The objective of this study was to fill this gap by gener...
Autores principales: | Wiśniowska, Barbara, Giebułtowicz, Joanna, Piotrowski, Roman, Kułakowski, Piotr, Polak, Sebastian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953460/ https://www.ncbi.nlm.nih.gov/pubmed/35337175 http://dx.doi.org/10.3390/ph15030379 |
Ejemplares similares
-
Characterization of In Vitro and In Vivo Metabolism of Antazoline Using Liquid Chromatography-Tandem Mass Spectrometry
por: Giebułtowicz, Joanna, et al.
Publicado: (2020) -
Magnetic Core–Shell Molecularly Imprinted Nano-Conjugates for Extraction of Antazoline and Hydroxyantazoline from Human Plasma—Material Characterization, Theoretical Analysis and Pharmacokinetics
por: Giebułtowicz, Joanna, et al.
Publicado: (2021) -
Pharmacological Cardioversion With Antazoline in Atrial Fibrillation: The Results of the CANT Study
por: Wybraniec, Maciej T., et al.
Publicado: (2018) -
PBPK Model for Atrazine and Its Chlorotriazine Metabolites in Rat and Human
por: Campbell, Jerry L., et al.
Publicado: (2016) -
Effect of Antazoline on Electrophysiological Properties of Atrial Muscle and Conduction System of the Heart
por: Bińkowski, Bartłomiej Jacek, et al.
Publicado: (2018)